Cytokinetics Files For IPO As Two Cancer Drugs Enter Clinic
With hopes of raising $86.25 million to advance two cancer drugs and a preclinical candidate for heart failure, Cytokinetics Inc. filed for its initial public offering. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.